Genetic Polymorphisms of ABCB11 and ABCB4 in Women With Intrahepatic Cholestasis of Pregnancy (ICP) and in Their First Degree Relatives

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2022-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the occurrence of 11 SNP's in ABCB11 and ABCB4 genes in Greek women with ICP compared with healthy pregnant women. Moreover, these genetic polymorphisms will be examined in their first-degree relatives.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ABCB4 Gene Mutations in Intrahepatic Cholestasis of Pregnancy and Controls

NCT00700232

Intrahepatic Cholestasis of Pregnancy

COMPLETED

Ursodeoxycholic Acid And Cholestasis Of Pregnancy

NCT01226823

Intrahepatic Cholestasis of Pregnancy

WITHDRAWN PHASE3

Association of Intrahepatic Cholestasis of Pregnancy and Chronic Placental Inflammation

NCT05197387

Cholestasis of Pregnancy

RECRUITING

The Metabolic Profile in Intrahepatic Cholestasis of Pregnancy and Diabetes Mellitus

NCT01499524

Intrahepatic Cholestasis of Pregnancy Gestational Diabetes Mellitus

COMPLETED

Gallbladder Functions & Serum Cholecystokinin Levels in Women Diagnosed With Hyperemesis Gravidarum

NCT03950167

Hyperemesis Gravidarum Pregnancy Related

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Introduction: ICP is commolnly manifested in the 2nd and especially in the 3rd trimester of pregnancy. Pathogenesis of ICP is multifactorial implicating genetic, environmental and hormonologic factors. Prevalence of ICP varies. In certain populations in latin America occurrence of ICP is up to 15% of pregnancies. In Caucasian populations incidence of ICP is approximately 1% of pregnancies. Data for the Greek population are scarce. Genes ABCB4 and ABCB11 that are encoding transport proteins in the hepatocyte are implicated in the pathogenesis of ICP.

Aim of the Study: To study the genetic polymorphisms in pregnant women with ICP and in their first degree relatives Patients and Methods: To recruit 100 women with ICP. Analyze the occurrence of 11 SNP's in ABCB11 and ABCB4 genes in women with ICP. As control group will be used pregnant women without ICP or known hepatic disease. In these women the same analysis for SNP's as in women with ICP will be performed. Exclusion criteria: women with known hepatic disease ( HBV, HCV, HIV, HEV, Autoimmune Hepatitis, Drug induced liver injury, cirrhosis) and women with pregnancy related liver disease (pre-eclampsia, acute fatty liver of pregnancy or HELLP syndrome) Inclusion criteria: pregnant women with ICP. Detailed report of medical history, laboratory and clinical data regarding women and the pregnancy. Follow up of laboratory values before and after the begging of treatment with UDCA.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cholestasis of Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ICP

To study the genetic polymorphisms in pregnant women with ICP and in their first degree relatives

ursofalk

Intervention Type DRUG

To study the genetic polymorphisms in pregnant women with ICP treated with ursoflak and in their first degree relatives

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ursofalk

To study the genetic polymorphisms in pregnant women with ICP treated with ursoflak and in their first degree relatives

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* pregnant women with ICP

Exclusion Criteria

* women with known hepatic disease ( HBV, HCV, HIV, HEV, Autoimmune Hepatitis, Drug induced liver injury, cirrhosis)
* women with pregnancy related liver disease (pre-eclampsia, acute fatty liver of pregnancy or HELLP syndrome)

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes